tisagenlecleucel
novartis
['fil,veral,12', 'tisa-cel', 'elara', 'lymphoma', 'tisagenlecleucel']
longer fu of tisa-cel in r/r fl (elara) - dreyling
- 2y fu, pfs, dor all nr
- no additional safety signals (feasible for op delivery)
- initial bulk disease less good
- absence of t-cell exhaustion markers (lag3) did better
very nice option for higher risk fl
#ash22 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.